FOXO4-DRI

Key Benefits#

• Selectively clears senescent cells (senolytics)
• Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
• Demonstrated restoration of physical fitness in aged mice
• May improve healthspan and reduce age-related tissue dysfunction
• Potential for treatment of age-related pathologies driven by cellular senescence
• Does not affect healthy non-senescent cells at therapeutic doses

Mechanism of Action#

Senescent cells survive by sequestering p53 in the nucleus via FOXO4 binding, preventing p53-mediated apoptosis. FOXO4-DRI is a competitive antagonist of this interaction — it penetrates cells, binds FOXO4, and disrupts the FOXO4-p53 complex. Released p53 translocates to mitochondria, triggering intrinsic apoptosis specifically in senescent cells. The D-retro-inverso configuration (all D-amino acids, reversed sequence) confers protease resistance for extended half-life.

Dosing Protocols#

Side Effects#

• Limited human data; largely preclinical evidence
• Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
• Weight loss observed at high doses in rodent studies
• Unknown long-term safety profile in humans

Contraindications#

No approved human use; research compound onlyActive cancer (p53 pathway manipulation; contraindicated)Immunosuppression (caution with immune modulation)Pregnancy: absolutely contraindicated

Storage#

Lyophilized: store at -20 degrees C, protected from light. Reconstituted: refrigerate at 2-8 degrees C and use within 14 days. Avoid freeze-thaw cycles.

1. 1.
   FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway

   Hu Z, Li F, Hu C, Shan Q, Tang Z, Jiang M et al. · Frontiers in bioengineering and biotechnology · 2025PubMed Verified

2. 2.
   The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI

   Bourgeois B, Spreitzer E, Platero-Rochart D, Paar M, Zhou Q, Usluer S et al. · Nature communications · 2025PubMed Verified

3. 3.
   FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation

   Kong YX, Li ZS, Liu YB, Pan B, Fu X, Xiao R et al. · Communications biology · 2025PubMed Verified

4. 4.
   FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells

   Li Y, Zhang C, Cheng H, Lv L, Zhu X, Ma M et al. · Experimental gerontology · 2024PubMed Verified

5. 5.
   Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia

   Jing X, Jia S, Teng M, Day BW, Afolayan AJ, Jarzembowski JA et al. · American journal of respiratory cell and molecular biology · 2024PubMed Verified

6. 6.
   FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice

   Liu Y, Hou Q, Wang R, Liu Y, Cheng Z · Naunyn-Schmiedeberg's archives of pharmacology · 2023PubMed Verified

7. 7.
   Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression

   Born E, Lipskaia L, Breau M, Houssaini A, Beaulieu D, Marcos E et al. · Circulation · 2023PubMed Verified

8. 8.
   Targeting Multiple Homeostasis-Maintaining Systems by Ionophore Nigericin Is a Novel Approach for Senolysis

   Deryabin PI, Shatrova AN, Borodkina AV · International journal of molecular sciences · 2022PubMed Verified

9. 9.
   FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway

   Han X, Yuan T, Zhang J, Shi Y, Li D, Dong Y et al. · Journal of cellular and molecular medicine · 2022PubMed Verified

10. 10.
    Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis

    Meng J, Li Y, Wan C, Sun Y, Dai X, Huang J et al. · JCI insight · 2021PubMed Verified

11. 11.
    Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

    Huang Y, He Y, Makarcyzk MJ, Lin H · Frontiers in bioengineering and biotechnology · 2021PubMed Verified

12. 12.
    FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice

    Zhang C, Xie Y, Chen H, Lv L, Yao J, Zhang M et al. · Aging · 2020PubMed Verified

13. 13.
    Cellular senescence as a therapeutic target to improve renal transplantation outcome

    van Willigenburg H, de Keizer PLJ, de Bruin RWF · Pharmacological research · 2018ReviewPubMed Verified

14. 14.
    Cellular senescence in the aging and diseased kidney

    Valentijn FA, Falke LL, Nguyen TQ, Goldschmeding R · Journal of cell communication and signaling · 2018ReviewPubMed Verified

15. 15.
    Rejuvenation by Therapeutic Elimination of Senescent Cells

    Krimpenfort P, Berns A · Cell · 2017PubMed Verified